Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

Date
2011
Author
Hansen, S.
De Bono, J. S.
Ozguroglu, M.
Machiels, J. H.
Shen, L.
Sartor, A. O.
Oudard, S.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/107294
https://doi.org/10.1200/jco.2011.29.15_suppl.4525
Collections